Latest news with #TVGN489
Yahoo
25-05-2025
- Business
- Yahoo
Tevogen Peports Plans to Increase the Target Population for TVGN 489
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) revealed plans to broaden the scope of its TVGN 489 experimental medication to encompass patients 65 years of age and above. A laboratory technician researching a sample of cells in a biotechnology laboratory. The action expands upon the company's October 2024 revenue forecast of around $1 billion in sales during the first year, with five-year projections ranging from $18 billion to $22 billion. The expanded market will be reflected in an updated risk-adjusted net present value. Sadiq Khan, MBA, Chief Commercial Officer, stated that the strategic choice coincides with a spike in instances of the highly contagious COVID variant NB.1.8.1, which was initially identified in China. Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is increasing clinical production to satisfy consumer demand. TVGN 489 targets SARS-CoV-2 infections in immunocompromised patients, such as those with psoriatic arthritis, rheumatoid arthritis, B-cell tumors, and other malignancies. It was created utilizing Tevogen Bio Holdings Inc. (NASDAQ:TVGN)'s ExacTcell™ platform. It covers Long COVID as well. Since seniors (65 and above) were not taken into consideration in earlier forecasts, their inclusion in the specialty care pipeline significantly boosts commercial potential. While we acknowledge the potential of TVGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TVGN and that has 100x upside potential, check out our report about this READ NEXT: and . Sign in to access your portfolio
Yahoo
07-02-2025
- Business
- Yahoo
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure
WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio's affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell's unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator Program Department of Defense - Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Antivirals and Antitoxins Branch within BARDA's Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Contacts Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701 Communications@ A video accompanying this announcement is available at
